DEA Weighs First-Ever LSD Import License for CalCog
Published Date: 6/8/2026
Notice
Summary
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Application to Import Schedule I Drugs
On April 30, 2026, CalCog Inc. (Bastrop, Texas) applied to be registered to import four Schedule I controlled substances: lysergic acid diethylamide (LSD, code 7315), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, code 7431), dimethyltryptamine (DMT, code 7435), and psilocyn (code 7438). The company says it plans to import these substances only as dosage units for clinical trials; the registration would not authorize other activities or importation of finished dosage forms for commercial sale.
Comment and Hearing Deadline for Stakeholders
Registered bulk manufacturers of the listed drug classes and other applicants may submit electronic comments or objections through Regulations.gov, or file written requests for a hearing, on or before July 8, 2026. Comments submitted electronically will receive a Comment Tracking Number; written hearing requests must be sent to the DEA Hearing Clerk and Administrator at the Springfield, Virginia addresses listed in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
Previous / Next Documents
Previous: 2026-11413 — Agency Information Collection Activities; Submission to the Office of Management and Budget; Northeast Region Hunter Participation Surveys
The U.S. Fish and Wildlife Service wants to keep collecting info from hunters in the Northeast to better understand hunting habits. This renewal won’t cost hunters money but helps the agency plan wildlife management smarter. If you have thoughts, you’ve got until July 8, 2026, to share them!
Next: 2026-11417 — Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just added Amir Hossein Rad from Iran to its sanctions blacklist, blocking all his U.S.-related property and banning Americans from doing business with him. At the same time, some folks got their names removed from the list, meaning their assets are now unblocked. These changes took effect on June 2, 2026, so watch out for new rules and restrictions that could impact money and deals fast!